Clinical Trials Logo
  1. Home
  2. Pulmonary Artery Hypertension
  3. NCT05421949

Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH — REPEAT-PAH  

Pulmonary Artery Hypertension Clinical Trial

Official title:
Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH (REPEAT-PAH)

Clinical Trial Summary

The purpose of this study is to examine N-terminal pro brain natriuretic peptide (NT-proBNP) and brain natriuretic peptide (BNP) biomarkers in a number of different settings including assessing the repeatability of laboratory and point of care testing (POCT), the effect of a time delay and exercise have on laboratory measurements. Also to compare the clinical and analytical performances of NT-proBNP and BNP POCT samples across the spectrum of disease severity and finally assess whether POCT in PAH can detect change in patients commencing or escalating PAH treatment.

Clinical Trial Description

- Patients that are attending clinical appointments will be approached to ask if they will take part in the study. - Patients will be assessed at two separate visits. - Patients will be randomised to either exercise or rest group on their 1st visit. On the 2nd visit patients will be asked to participate in the alternate group to what they completed on their previous visit. - At each visit they will have 2 blood samples taken, at time point 1 and at time point 2 (T1 and T2). These will be taken at least one hour apart, each with a period of at least 15 mins rest in the sitting position prior to sampling. - On one of these two visits the patient will undergo exercise testing between T1 and T2. - In addition, a further laboratory testing tube will be taken for a delayed NT-proBNP. This will be subjected to gentle agitation (laboratory rotator) for 48 hours prior to processing to simulate, in a controlled environment, the effect of transport and delay on sample measurement. - Retrospectively information will be collected regarding the patient's disease severity and any change to treatment that occurred between the two visits. - A total of 40 patients with be sampled with an interim analysis after 20 patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05421949
Study type Observational
Source Sheffield Teaching Hospitals NHS Foundation Trust
Contact
Status Completed
Phase
Start date February 19, 2021
Completion date August 30, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT05056532 - Evaluation of Respiratory Muscle in Patient With Pulmonary Arterial Hypertension
Active, not recruiting NCT06003244 - High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT) N/A
Active, not recruiting NCT06072417 - HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level) N/A
Recruiting NCT02966665 - : Vascular Function in Health and Disease Phase 1
Recruiting NCT00502398 - Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension? N/A
Completed NCT04456998 - GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) Phase 2
Not yet recruiting NCT06035861 - Endothelial Cell Activation and Total Pulmonary Resistance in PAH N/A
Recruiting NCT03138863 - Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO) N/A
Recruiting NCT02102672 - Trimetazidine in Pulmonary Artery Hypertension Phase 2
Withdrawn NCT06122922 - Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN) Phase 2
Recruiting NCT03195543 - Assessment of Blood Coagulation Disorders in Patients With Pulmonary Hypertension
Completed NCT04337671 - Impact of Aerobic Training on Sleep Quality and Aerobic Fitness in Male Patients With Pulmonary Artery Hypertension N/A
Completed NCT03198910 - Retrospective Data Analysis of Data From the Zurich PH Registry
Completed NCT03979482 - Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH
Active, not recruiting NCT06084559 - HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT) N/A
Active, not recruiting NCT05996302 - HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level) N/A
Withdrawn NCT02684786 - A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension Phase 1
Not yet recruiting NCT06258850 - REstoration of VItamin D in Pulmonary Arterial Hypertension Phase 4
Completed NCT04094272 - Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection
Active, not recruiting NCT01763112 - Training With Whole Body Vibration Device in Patients With PAH N/A